Aposan Dr. Kuenzer GmbH is a pharmaceutical manufacturer under § 13 AMG operating nationwide in Germany and produces parenteral nutrition solutions, antibiotic and other active-substance infusions as well as patient-specific formulations. The company focuses on outpatient care of critically ill patients and additionally supplies patients with enteral nutrition. Manufacturing follows European GMP standards and distribution is carried out mainly via pharmacies and payers, as over 90% of receivables arise from revenues with pharmacies or payers. In fiscal year 2015 the gross result amounted to EUR 11,340,394.14 and the net profit to EUR 3,315,379.53; the average number of employees in 2015 was 114.
die Herstellung von und der Handel mit Arzneimitteln sowie der Handel mit Heil- und Hilfsmitteln und deren diesbezügliche Beratung. Handel und Beratung mit Arzneimitteln werden nur in dem Umfang betrieben, der nach dem Arzneimittelgesetz erlaubt ist, oder für den zusätzliche Genehmigungen vorliegen.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 25157 (as of 2 November 2026)
| Name | Type | City |
|---|---|---|
| Susanne Roeb | Geschäftsführer(in) | Düren |
| Martin Schulze | Geschäftsführer(in) | Köln |
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 25157 (as of 2 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2015 | Rohergebnis€11.3M2 | €3,315,380 | €11,462,174 | — |
| 2014 | Rohergebnis€9.8M2 | €5,154,622 | €11,724,047 | — |
| 2013 | Rohergebnis€8M2 | €1,614,389 | €9,861,904 | — |
| 2012 | Rohergebnis€6.8M2 | €1,003,138 | €8,399,040 | — |
| 2011 | Rohergebnis€9.6M2 | €984,915 | €7,440,414 | — |
| 2010 | Rohergebnis€9.3M2 | €1,495,698 | €7,850,377 | — |
| 2009 | ≤ €12M1 | €1,227,341 | €6,461,556 | — |
| 2008 | small company1 | €924,660 | €4,746,237 | — |
| 2007 | small company1 | €559,462 | €4,321,624 | — |
| 2006 | small company1 | €419,422 | €3,845,465 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Köln Local Court, HRB 25157 (as of 2 November 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €4,556,276 | 88.8% |
| Depreciation | €576,635 | 11.2% |
| Interest & Similar | €41 | 0.0% |
